Compare AMPX & STOK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPX | STOK |
|---|---|---|
| Founded | 2008 | 2014 |
| Country | United States | United States |
| Employees | 109 | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.0B |
| IPO Year | N/A | 2019 |
| Metric | AMPX | STOK |
|---|---|---|
| Price | $11.57 | $31.50 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 10 |
| Target Price | $20.17 | ★ $39.20 |
| AVG Volume (30 Days) | ★ 7.3M | 1.0M |
| Earning Date | 05-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 92.73 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $184,420,000.00 |
| Revenue This Year | $76.15 | N/A |
| Revenue Next Year | $59.65 | $77.49 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 404.50 |
| 52 Week Low | $6.09 | $11.66 |
| 52 Week High | $24.23 | $40.22 |
| Indicator | AMPX | STOK |
|---|---|---|
| Relative Strength Index (RSI) | 35.81 | 49.70 |
| Support Level | $10.00 | $30.34 |
| Resistance Level | $14.54 | $32.35 |
| Average True Range (ATR) | 1.16 | 1.55 |
| MACD | -0.14 | 0.12 |
| Stochastic Oscillator | 6.39 | 39.45 |
Amprius Technologies Inc is engaged in the production of silicon anodes for high-energy-density lithium-ion batteries. The company develops, manufactures and markets lithium-ion batteries for mobility applications, including the aviation, electric vehicle (EV) and light electric vehicle (LEV) industries. The company's batteries are used for existing and emerging aviation applications, including unmanned aerial systems, such as drones and high-altitude pseudo satellites. Its silicon anodes are a direct drop-in replacement of the graphite anode in traditional lithium-ion batteries, and its manufacturing processes leverage the manufacturing processes for conventional lithium-ion batteries and the related supply chain.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.